-
Mar202116
Prometheus Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Mar202111
Prometheus Biosciences Announces Upsized Pricing of Initial Public Offering
-
Mar202104
Prometheus Biosciences Announces Appointment of Mark Stenhouse as Chief Operating Officer
-
Mar202103
Prometheus Biosciences Commences Dosing in Multiple Ascending Dose (MAD) Portion of Ongoing Phase 1a Clinical Study of PRA023
-
Feb202116
Prometheus Biosciences Announces Appointments of Judith L. Swain, MD and Helen C. Adams, CPA to its Board of Directors
-
Dec202015
Prometheus Biosciences Announces FDA Acceptance of IND Application for PRA023 and Commences Dosing in Phase 1a Clinical Study
-
Nov202009
Prometheus Biosciences Announces $130 Million Financing to Advance Precision Medicines for the Treatment of Inflammatory Bowel Disease
-
Sep202029
Prometheus Biosciences Appoints Olivier Laurent, Ph.D. as Chief Technology Officer
-
Aug202025
Prometheus Biosciences Appoints Joseph C. Papa to its Board of Directors
-
Aug202013
Prometheus Biosciences and Dr. Falk Pharma GmbH Announce Global Collaboration Agreement to Develop and Commercialize a Novel IBD Antibody